Eli Lilly’s stock plummets over missed sales forecasts for Mounjaro, Zepbound – what’s next for the pharma giant?

Eli Lilly’s stock plummets over missed sales forecasts for Mounjaro, Zepbound – what’s next for the pharma giant?

Eli Lilly & Co. has faced a dramatic drop in its stock price, tumbling over 10% following a critical earnings report that highlighted missed revenue targets for two of its most anticipated drugs: Mounjaro, a diabetes medication, and Zepbound, a high-profile weight-loss drug. Investors, who had anticipated a robust sales report amid growing demand for […]

Biocon joins forces with Tabuk Pharmaceuticals to bring GLP-1 diabetes drugs to Middle East

Biocon joins forces with Tabuk Pharmaceuticals to bring GLP-1 diabetes drugs to Middle East

In a strategic move to tackle the growing diabetes crisis in the Middle East, Biocon Limited has announced a partnership with Tabuk Pharmaceutical Manufacturing Company. This alliance aims to commercialize Biocon’s Glucagon-like peptide-1 (GLP-1) products across the Middle East, specifically focusing on Saudi Arabia and neighboring regions. GLP-1 products, which are increasingly recognized for their […]

LifeVantage stock soars on game-changing GLP-1 study results – here’s what you need to know

LifeVantage stock soars on game-changing GLP-1 study results – here’s what you need to know

Shares of LifeVantage Corporation have jumped 8.2% after the company announced encouraging results from a study on its new two-product system designed to boost GLP-1 production. The stock, which was trading around $9.23, has risen by 51% so far this year. The study results have created a buzz in both the health and investment communities, […]